Evidence map›Paper›PMID 25666032›Full record

ArticleNeuropharmacology2015

The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice.

Angélica Maria Sabogal-Guáqueta, Juan Ignacio Muñoz-Manco, Jose R Ramírez-Pineda, Marisol Lamprea-Rodriguez, Edison Osorio, Gloria Patricia Cardona-Gómez

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
198citing papers in PubMed, 3 pooled it
16.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

198 citing papers in PubMed, 3 syntheses or guidelines pooled it, 437 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Investigation of the Potential Neuroprotective Mechanisms ofInternational journal of molecular sciences · 2026
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Alzheimer's disease prevention by flavonols and their analogs.The journal of prevention of Alzheimer's disease · 2026
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

138 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Angélica Maria Sabogal-GuáquetaNeuroscience Group of Antioquia, Cellular and Molecular Neurobiology Area, Faculty of Medicine, University of Antioquia, Calle 70 No. 52-21, Medellin, Colombia.
Juan Ignacio Muñoz-MancoNeuroscience Group of Antioquia, Cellular and Molecular Neurobiology Area, Faculty of Medicine, University of Antioquia, Calle 70 No. 52-21, Medellin, Colombia.
Jose R Ramírez-PinedaGrupo de Investigación en Sustancias Bioactivas, Facultad de Química Farmacéutica, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medellín, Colombia; Group of Immunomodulation, Faculty of Medicine, University of Antioquia, Calle 70 No. 52-21, Medellin, Colombia.
Marisol Lamprea-RodriguezNeuroscience Laboratory, Psychology Department, Universidad Nacional de Colombia, Bogotá, Colombia.
Edison OsorioGrupo de Investigación en Sustancias Bioactivas, Facultad de Química Farmacéutica, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medellín, Colombia.
Gloria Patricia Cardona-GómezNeuroscience Group of Antioquia, Cellular and Molecular Neurobiology Area, Faculty of Medicine, University of Antioquia, Calle 70 No. 52-21, Medellin, Colombia. Electronic address: patricia.cardonag@udea.edu.co.
Universidad de Antioquia · COUniversidad Nacional de Colombia · CO

Funding

Development of RNAi as Treatment for NeurodegenerationR01AG029802 · NIA · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI KOSIK, KENNETH STEPHEN · 2007 to 2011
$674k
NIA NIH HHS 1 R01 AG029802-01NIA NIH HHS R01 AG029802
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common senile dementia in the world. Although important progress has been made in understanding the pathogenesis of AD, current therapeutic approaches provide only modest symptomatic relief. In this study, we evaluated the neuroprotective effect of quercetin (25 mg/kg) administration via i.p. injection every 48 h for 3 months on aged (21-24 months old) triple transgenic AD model (3xTg-AD) mice. Our data show that quercetin decreases extracellular β-amyloidosis, tauopathy, astrogliosis and microgliosis in the hippocampus and the amygdala. These results were supported by a significant reduction in the paired helical filament (PHF), β-amyloid (βA) 1-40 and βA 1-42 levels and a decrease in BACE1-mediated cleavage of APP (into CTFβ). Additionally, quercetin induced improved performance on learning and spatial memory tasks and greater risk assessment behavior based on the elevated plus maze test. Together, these findings suggest that quercetin reverses histological hallmarks of AD and protects cognitive and emotional function in aged 3xTg-AD mice.

Indexed as

AgingAlzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsAntioxidantsBrainCognition DisordersDisease Models, AnimalDrug Administration ScheduleGliosisMaze LearningMiceMice, TransgenicMood DisordersNerve Tissue ProteinsAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAntioxidantsNerve Tissue ProteinsPresenilin-1Quercetintau ProteinsAlzheimer's diseaseCognitive functionNeuroprotectionQuercetinTauopathyβ-amyloidosis

Identifiers

PMID25666032
PMCPMC4387064
OpenAlexW2039851764

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.